The paradox of the low-renin state in diabetic nephropathy - PubMed

Affiliations

• PMID: 10541298
• DOI: 10.1681/ASN.V10112382

The paradox of the low-renin state in diabetic nephropathy

D A Price et al. J Am Soc Nephrol. 1999 Nov.

Abstract

Although diabetic nephropathy is often a low renin state, the renin system appears to be implicated in its pathogenesis. In this study, it was hypothesized that the low plasma renin activity (PRA) is misleading, masking and perhaps reflecting an activated intrarenal renin system. PRA and renal vascular responses (inulin and para-aminohippurate clearance) to graded doses of an angiotensin II (AngII) antagonist, irbesartan, were assessed in eight healthy volunteers and 12 patients with type 2 diabetes mellitus and nephropathy on a 10 mmol Na intake, to activate the renin system. Basal PRA was suppressed in type 2 diabetes mellitus compared with the healthy subjects (0.58 +/- 0.14 versus 1.58 +/- 0.28 ng/L per s, mean +/- SEM; P < 0.01). Despite the low PRA, renal perfusion rose more in response to irbesartan in type 2 diabetes mellitus (714 +/- 83 to 931 +/- 116 ml/min; P = 0.002) than normal (624 +/- 29 to 772 +/- 49 ml/min; P = 0.008). The youngest patients were hyperfiltrating and showed the largest rise in renal plasma flow in response to irbesartan, whereas renal plasma flow rose less and GFR fell in patients with low basal GFR. PRA rose in response to irbesartan more gradually in the patients with type 2 diabetes mellitus, but ultimately matched the normal response. To account for the apparent paradox of a heightened renal hemodynamic response to an AngII antagonist in the face of a low PRA in type 2 diabetes mellitus, and the rise in PRA following the AngII antagonist, it is proposed that there is increased intrarenal AngII production in type 2 diabetes mellitus. This increase could account for suppressed circulating renin, the exaggerated renal vasodilator response to irbesartan, and the therapeutic effectiveness of interrupting the renin system in diabetic nephropathy.

Similar articles

• Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan.

  Price DA, Lansang MC, Osei SY, Fisher ND, Laffel LM, Hollenberg NK. Price DA, et al. Diabet Med. 2002 Oct;19(10):858-61. doi: 10.1046/j.1464-5491.2002.00806.x. Diabet Med. 2002. PMID: 12358875

• Failure of angiotensin II to suppress plasma renin activity in normotensive subjects with a positive family history of hypertension.

  Herlitz H, Palmgren E, Widgren B, Aurell M. Herlitz H, et al. Clin Sci (Lond). 2005 Sep;109(3):311-7. doi: 10.1042/CS20050055. Clin Sci (Lond). 2005. PMID: 15901242

• The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus.

  Price DA, De'Oliveira JM, Fisher ND, Williams GH, Hollenberg NK. Price DA, et al. Am J Hypertens. 1999 Apr;12(4 Pt 1):348-55. Am J Hypertens. 1999. PMID: 10232494 Clinical Trial.

• The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.

  Zanella MT, Ribeiro AB. Zanella MT, et al. Clin Ther. 2002 Jul;24(7):1019-34. doi: 10.1016/s0149-2918(02)80016-9. Clin Ther. 2002. PMID: 12182249 Review.

• Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

  Lewis EJ, Lewis JB. Lewis EJ, et al. Clin Exp Nephrol. 2003 Mar;7(1):1-8. doi: 10.1007/s101570300000. Clin Exp Nephrol. 2003. PMID: 14586737 Review.

Cited by

• Recent advances in tissue (pro)renin imaging.

  Prokai A, Peti-Peterdi J. Prokai A, et al. Front Biosci (Elite Ed). 2010 Jun 1;2(4):1227-33. doi: 10.2741/e182. Front Biosci (Elite Ed). 2010. PMID: 20515794 Free PMC article. Review.

• The Absence of the ACE N-Domain Decreases Renal Inflammation and Facilitates Sodium Excretion during Diabetic Kidney Disease.

  Eriguchi M, Bernstein EA, Veiras LC, Khan Z, Cao DY, Fuchs S, McDonough AA, Toblli JE, Gonzalez-Villalobos RA, Bernstein KE, Giani JF. Eriguchi M, et al. J Am Soc Nephrol. 2018 Oct;29(10):2546-2561. doi: 10.1681/ASN.2018030323. Epub 2018 Sep 5. J Am Soc Nephrol. 2018. PMID: 30185469 Free PMC article.

• A case of idiopathic nodular glomerulosclerosis successfully treated by intensive blockade of the renin-angiotensin-aldosterone system.

  Yamaguchi H, Hosojima M, Kabasawa H, Ito Y, Suzuki Y, Saito A, Arakawa M, Narita I. Yamaguchi H, et al. CEN Case Rep. 2023 Aug;12(3):311-317. doi: 10.1007/s13730-022-00766-3. Epub 2022 Dec 27. CEN Case Rep. 2023. PMID: 36574195 Free PMC article.

• A mechanism for salt-sensitive hypertension: abnormal dietary sodium-mediated vascular response to angiotensin-II.

  Chamarthi B, Williams JS, Williams GH. Chamarthi B, et al. J Hypertens. 2010 May;28(5):1020-6. doi: 10.1097/HJH.0b013e3283375974. J Hypertens. 2010. PMID: 20216091 Free PMC article.

• Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells.

  Zhang J, Noble NA, Border WA, Owens RT, Huang Y. Zhang J, et al. Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E810-9. doi: 10.1152/ajpendo.90264.2008. Epub 2008 Jul 29. Am J Physiol Endocrinol Metab. 2008. PMID: 18664599 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wolters Kluwer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal